A Connecticut Federal Court recently decided Cross Motions for Summary Judgment in favor of the Plaintiff in a medical marijuana matter involving Connecticut’s medical marijuana law. Noffsinger v. SSC Niantic Operating Co., LLC. d/b/a Bride Brook Health and Rehab. Ctr., 2018 U.S. Dist. LEXIS 150453 (D. Conn. Sept. 5, 2019).
The government is seeking to tackle the opioid crisis with a crackdown on the production of prescription opioids permitted to be manufactured next year.
In a release, the Department of Justice and the U.S. Drug Enforcement Administration proposes slashing "manufacturing quotas for the six most frequently misused opioids for 2019 by an average ten percent as compared to the 2018 amounted," according to an advance version of the release viewed by Axios.
"We are trying to make the establishment of impairment around marijuana rational and to balance fairness and safety," CEO Mike Lynn told NPR, explaining that his company has created a breath test to detect THC, the principal psychoactive ingredient in cannabis
Laura Dashner, CEO & President and Sandra Serrano, Chief Development Officer are presenting "An Interview with Sandra Sapp" at 4pm on September 25th at the SAPAA Conference in Kansas City, Missouri.
Researchers have found out that since the prescription opioid crackdown began, sales from dark web sales for the targeted medications have steadily increased. A new study has found the rules meant to crack down on the use of opioids have turned some individuals to the black market.
Alcohol is the most widely used drug in the world, including in the United States.
International Overdose Awareness Day (IOAD) is a global event held on August 31st each year and aims to raise awareness of overdose and reduce the stigma of a drug-related death.
It also acknowledges the grief felt by families and friends remembering those who have met with death or permanent injury as a result of drug overdose.
Overdose Day spreads the message that the tragedy of overdose death is preventable. Wear Silver to show your support.
By the end of this year, more than three dozen communities across the country will have begun participation in a national initiative designed to bring together a diversity of stakeholders to solve local problems related to addiction.
In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The Helping to End Addiction Long-term (HEAL) initiative is being kicked off today with the announcement of several bold projects across NIH, focused on two main areas: improving opioid addiction treatments and enhancing pain management to prevent addiction and overdose.
More people now die from overdosing on synthetic opioids – mainly fentanyl – than prescription painkillers, according to a recent study.
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, is pleased to announce that lofexidine, the first medication for use in reducing symptoms associated with opioid withdrawal in adults, has been approved by the U.S. Food and Drug Administration. Lofexidine, an oral tablet, is designed to manage the symptoms patients often experience during opioid discontinuation.
ASAP is going to New Orleans and will be at Booth 602, so stop by and visit!
Join your colleagues and industry experts for the industry’s premier educational event. With Over 800 attendees, 85 exhibitors, 25 educational sessions, and pre- and post-conference trainings this is your one-stop shop for staying current on what’s happening in the drug and alcohol testing industry. Learn More
The State of Maine Department of Labor has published a guide on marijuana in the workplace on their website
A provision of Maine’s recreational marijuana law prohibits employers from taking adverse employment actions for off-premises marijuana use, as of February 1, 2018. This law effectively prevents Maine employers from testing for marijuana for pre-employment purposes. The law also affects employers who employ employees subject to federal drug and alcohol testing regulations as well as those employers who are exempt from complying with Maine’s drug testing law.
One of the pillars of the current federal initiatives to end the opioid crisis is the development of new medications to treat opioid addiction. Currently we have three approved drugs—methadone, buprenorphine, and naltrexone—in a growing number of formulations, including some that are extended-release (long acting). But not all patients respond to the existing medications, and each patient has unique needs.
DOT Update: Only the Federal Drug Testing Custody and Control Form approved on August 8, 2017, can be used after June 30, 2018
On August 8, 2017, the Office of Management and Budget approved a revised Federal Drug Testing Custody and Control Form (CCF) and authorized the continued use of the `old CCF’ until June 30, 2018.
DOT regulated employers and their service agents (collectors, laboratories, Medical Review Officers) may not use the `old CCF’ for DOT mandated drug test collections after June 30, 2018.
What is the difference between the revised and ‘old’ CCF?